Reshaping the HIV treatment and prevention landscape

Major opportunities in pre-exposure prophylaxis (PrEP) Cabotegravir for PrEP: offers potential to transform the shape of the epidemic LA injectable PrEP market £4-5bn by 2030 - - US political will to end epidemic by 2030 First LA injectable PrEP administered every two months Cabotegravir superior in men and women vs. daily oral Truvada Cab for PrEP filed with US FDA in H1 with expected launch in early 2022 Cabotegravir LA superior to daily oral standard of care Cumulative Incidence 0.01 0.02 0.03 0.04 0.05 0.06 0.07 0.08 HR:0.11 (0.01, 0.31) P=0.000027 0 gsk 0917 25 33 41 49 57 65 73 81 89 97 105 113 121 129 137 145 153 Weeks since Enrollment - Truvada -- Cabotegravir 77

View entire presentation